Suven Life Sciences Limited

119.83

INR
-0.16(-0.13%)
As of November 14, 2024 10:00:00 AM

Suven Life Sciences Limited Share Price Information

24 hour Low and High

Low: 119.41
High: 128

All time High

164.66

Price Change 1h

+₹-6.23 +-4.94%

Price Change 1d

+₹-6.23 +-4.94%

Price Change 1w

+₹-11.05 +-8.44%

Suven Life Sciences Limited Market Information

Exchange

NSE

Market Cap

2711.06 Cr

About Suven Life Sciences Limited Share

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

141

CEO

Mr. Venkateswarlu Jasti M.Pharm. M.S.

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • Suven Life hits life high after positive result for its depression drug
  • Top Stock Recommendations: Osho Krishan of Angel One suggests buying Suven Life Sciences, and Sutlej Textiles today | Stock Market News
  • Suven Life Sciences' Stock Continues to Decline, Underperforming Sector and Sensex
  • Stocks in news: SpiceJet, Shriram Finance, Suven Pharma, Mazagon Dock, Suzlon Energy
  • Cohance Lifesciences merger with Suven Pharma gets NSE, BSE nod

FAQs

Suven Life Sciences Limited

119.83

INR
-0.16(-0.13%)
As of November 14, 2024 10:00:00 AM

Suven Life Sciences Limited Share Price Information

24 hour Low and High

Low: 119.41
High: 128

All time High

164.66

Price Change 1h

+₹-6.23 +-4.94%

Price Change 1d

+₹-6.23 +-4.94%

Price Change 1w

+₹-11.05 +-8.44%

Suven Life Sciences Limited Market Information

Exchange

NSE

Market Cap

2711.06 Cr

About Suven Life Sciences Limited Share

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

141

CEO

Mr. Venkateswarlu Jasti M.Pharm. M.S.

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • Suven Life hits life high after positive result for its depression drug
  • Top Stock Recommendations: Osho Krishan of Angel One suggests buying Suven Life Sciences, and Sutlej Textiles today | Stock Market News
  • Suven Life Sciences' Stock Continues to Decline, Underperforming Sector and Sensex
  • Stocks in news: SpiceJet, Shriram Finance, Suven Pharma, Mazagon Dock, Suzlon Energy
  • Cohance Lifesciences merger with Suven Pharma gets NSE, BSE nod

FAQs